SeaStar Medical (ICU) Stock: Buy, Sell, or Hold?
ICU - SeaStar Medical Holding Corporation Common Stock
$2.41
-0.44 (-15.44%)
▼
5d:
-16.9%
30d:
-29.94%
90d:
-32.49%
WAIT
LOW Confidence
Analysis Updated: Oct 23, 2026 12:00 AM ET
Earnings: Nov 12, 2026
18d
Get Alerted When ICU Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: ICU is down 16.9% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: ICU is down 16.9% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: ICU is currently trading at $2.41, which is considered oversold relative to its 30-day fair value range of $2.98 to $3.81.
Technical Outlook: Technically, ICU is in a downtrend. The price is currently testing key support at $2.40. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 15.4% recently.
Market Sentiment: The stock scores a mixed 40/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $10.00 (+314.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, ICU is in a downtrend. The price is currently testing key support at $2.40. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 15.4% recently.
Market Sentiment: The stock scores a mixed 40/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $10.00 (+314.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$2.98 -
$3.81
Company Quality Score
45/100
(HOLD)
Volume Confirmation
MODERATE
Confidence Score
72.1%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BEARISH: Downward momentum (-15.4%)
- BULLISH: Trading 314.9% below Wall St target ($10.00)
- WARNING: Composite score 45/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$2.98 -
$3.81
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$2.40
Resistance Level
$3.95
Current Trend
Downtrend
Technical data as of
Oct 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.03
Wall Street Target
$10.00
(+314.9%)
Revenue Growth (YoY)
82.0%
Share & Embed Analysis
Last updated: October 24, 2026 4:45 AM ET
Data refreshes hourly during market hours. Next update: 5:45 AM
Data refreshes hourly during market hours. Next update: 5:45 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ICU showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
RVMD
Revolution Medicines Inc |
STRONG BUY
24 analysts |
$258 | 61 BUY |
|
IONS
Ionis Pharmaceuticals Inc |
STRONG BUY
25 analysts |
$84 | 61 BUY |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
21 analysts |
$95 | 50 HOLD |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 50 HOLD |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$72 | 48 HOLD |
